If you are a CDMO serving the biologics outsourcing market, or a PE company or investor looking to define your investing strategy, you need our 2021 Monoclonal Antibody & Recombinant Protein Market Report & CDMO Pricing Study to bolster your understanding of your competitive arena, assess how you measure up on pricing, and position your company effectively to get on shortlists. The 2021 Monoclonal Antibody & Recombinant Protein Market Report & CDMO Pricing Study extends Nice Insight’s 2019 CDMO Biologics Report with updated, current pricing data and assessments of how the market has shifted over the last two years. Access current pricing data that is typically impossible to come by.
If you are an innovator – large or small/virtual – looking to outsource your biologics development and manufacturing, our 2021 Monoclonal Antibody & Recombinant Protein Market Report & CDMO Pricing Study is a rich resource for introduction and information on 85 Biologics CDMOs that might be ideal for you. Whether you purchased the 2019 report or not, the current, 2021 pricing data will help you understand what you should pay with competitive pricing comparisons.
Pricing benchmarks cover line items under: